Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)

Prior treatment

• Moderate or severe cardiovascular disease meeting one or both of the below criteria:
  • Presence of cardiac disease, including a myocardial infarction within 6 months prior to study entry, unstable angina pectoris, New York Heart Association Class III/IV congestive heart failure, or uncontrolled hypertension
  • Documented major electrocardiogram (ECG) abnormalities (not responding to medical treatments)
• Participants who have undergone a hematopoietic cell transplant (HCT) within 100 days of the first dose of study therapy, participants on immunosuppressive therapy post-HCT at screening, use of calcineurin inhibitors within 4 weeks prior to first dose of study therapy, or participants with clinically significant graft-versus-host disease (GVHD)
  • o Note: The use of topical steroids or \< 10mg oral prednisone for ongoing skin GVHD is permitted
• Organ transplant recipients other than bone marrow transplant

Other illness

• History of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia requiring medication or mechanical control within the last 6 months
• Other invasive malignancies within the last 3 years, except non-melanoma skin cancer and localized cured prostate and cervical cancer
• Presence of active serious infection
• Known history of human immunodeficiency virus (HIV), or known active hepatitis A, B, or C infection
• Impairment of gastrointestinal (GI) function or GI disease that could significantly alter the absorption of reparixin, including any unresolved nausea, vomiting, or diarrhea \> CTCAE grade 1
• History of splenectomy
• Known hypersensitivity to sulfonamides
  • o Hypersensitivity to sulphanilamide antibiotics alone (e.g. sulfamethoxazole) does not qualify for exclusion
• Known hypersensitivity to non-steroidal anti-inflammatory drugs (NSAID), including ibuprofen

Lab values

• Any serious, unstable medical or psychiatric condition that would prevent (as judged by the Investigator) the participant from signing the ICF or any condition, including the presence of laboratory abnormalities, which places the participant at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study

Other

• Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or sponsor staff directly involved with this trial, unless prospective institutional review board (IRB) approval (by chair or designee) is given allowing exception to this criterion for a specific participant
• Women who are pregnant or lactating

• Be ≥ 18 years of age at time of signing the informed consent form (ICF)
• Willing to voluntarily sign the ICF
• Have a pathologically confirmed diagnosis of PMF, post-ET-MF, or post-PV-MF as per the World Health Organization (WHO) diagnostic criteria with intermediate-2 or higher risk disease by DIPSS
• Have an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
• Willing to undergo a bone marrow biopsy at screening
  • o A bone marrow biopsy obtained within 90 days of screening without intervening treatments and approved by the study chair may suffice.
• Be refractory/resistant to or intolerant of/inappropriate for JAKi therapy as defined by at least one of the following:
  • Treatment for ≥ 3 months with inadequate efficacy as demonstrated by persistent palpable splenomegaly ≥ 5cm or symptoms related to splenomegaly,
  • Treatment for ≥ 28 days complicated by either:
  • Development of a red blood cell transfusion requirement (at least 2 units/month for 2 months)
  • CTCAE grade ≥ 3 AEs of thrombocytopenia, anemia, hematoma, or hemorrhage while being treated with a JAKi
  • Development of non-hematological toxicity that makes patient intolerant of JAKi therapy
  • In the Investigator's judgment, are not candidates for available approved JAKi
• Recovery to ≤ Grade 1 or baseline of any toxicities due to prior systemic treatments, excluding alopecia
• At least two weeks must have elapsed between the last dose of any MF-directed drug treatments or other investigational therapies and start of reparixin
  • o Participants may continue hydroxyurea until the day prior to C1D1 if needed for disease control
• Have adequate organ function as demonstrated by the following:
  • ALT (SGPT) and/or AST (SGOT) ≤ 3x upper limit of normal (ULN), or ≤ 4 x ULN (if upon judgment of the treating physician, it is believed to be due to MF-related EMH);
  • Direct bilirubin ≤ 1.5 x ULN; or ≤ 2x ULN (if upon judgment of the treating physician, it is believed to be due to MF-related EMH or documented Gilbert's syndrome);
  • Creatinine clearance ≥ 40 mL/min;
  • Platelet count ≥ 25 x 109/L;
  • Bone marrow and peripheral blood blast count \< 10%;
  • ANC ≥ 1000 mm3.
• Life expectancy of at least six months
• Women of childbearing potential (WCBP) and men must agree to use adequate contraception prior to study entry, for the duration of study participation, and for 120 days following completion of therapy. WCBP must also have a negative serum pregnancy test at screening and Cycle 1 Day 1. Should a woman become pregnant or suspect she is pregnant while participating, she should inform her treating physician immediately. (Section 5.9.2)
  • o Men must agree to use a condom and not father a child or donate sperm for the duration of the study and for 120 days after the last dose of study therapy
• Ability to adhere to the study visit schedule and all protocol requirements